In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

Kepler Capital analyst David Evans maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) on October 30 and set a price ...

Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...

The US Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups.

Phenylephrine:CVS pulls cold medicines with the ingredient Companies such as Procter & Gamble and GSK were among several accused ... or remove such drugs from the market. The Consumer Healthcare ...

Nigeria, the giant of Africa, has recently experienced a great downturn in its economy, leading to the exodus of several ...

Four of the top 5 selling products of GSK are antibiotics ... it announced a big investment in creating a separate consumer goods unit. This solidified GSK as a "here-to-stay" company in the ...

Listing Sanofi and GlaxoSmithKline as firms that left the country due to the naira devaluation, the report said the continued weakness of the currency would increase medical device import costs and ...

23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and ...

The global glucosamine supplement market is projected to grow from USD 583.6 million in 2023 to USD 932.7 million by 2033, expanding at a CAGR of 4.8%, according to Future Market Insights. The rising ...

OMRON Healthcare, Inc. maker of the number one blood pressure monitor brand in the U.S. and Canada, today announced the ...